Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • Chapter 1 - Neuromuscular Diseases: Anterior Horn Cell Disorders, Peripheral Neuropathies, Neuromuscular Junction Disorders, Myopathies

  • from Part I - Evaluation and Treatment of Patients with a Neuromuscular Disorder
  • Jessica E. Hoogendijk, University Medical Center Utrecht, Marianne de Visser, Amsterdam University Medical Center, Pieter A. van Doorn, Erasmus MC, University Medical Center, Rotterdam, Erik H. Niks, Leiden University Medical Center
  • Book:
    Neuromuscular Disease
    Published online:
    29 November 2024
    Print publication:
    19 December 2024, pp 1-4
    • Chapter
      • You have access
    • HTML
    • Export citation

  • Summary

    Currently, there is a rapid, ongoing increase in our understanding of genetic neuromuscular disorders at the molecular level: many causative genes have been found, giving hope for targeted genetic treatments, already proven effective in some diseases. In immune-mediated neuromuscular disorders, pathogenetic mechanisms are better understood, and this enables the development of more precise immunotherapies. Increased knowledge has led to a refinement of classifications and has added numerous subtypes to the already hundreds of possible neuromuscular diagnoses. Patients can only benefit from future targeted therapies if an accurate diagnosis is made. Moreover, a diagnosis needs not only to be precise; the diagnostic trajectory needs to be swift, as current and future treatments will be aimed at the prevention or the restriction of irreversible damage.

    The best way to diagnose a neuromuscular disease at this point is probably to recognize the phenotypical pattern, to know its differential diagnosis, and to proceed from there.